CADASILに対するアドレノメデュリン

基本情報

NCT ID

NCT06072118

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

60

治験依頼者名

National Cerebral and Cardiovascular Center, Japan

概要

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common form of hereditary cerebral small vessel disease, with no proven disease-modifying treatments. Adrenomedullin, a vasoactive peptide, has angiogenic, vasodilation, anti-inflammatory, and anti-oxidative properties and could have triple sites of action on components of the neuro-glial-vascular unit consisting of vessels, microglia and oligodendrocytes or, more specifically, on the white matter oligovascular unit. The aim of the AMCAD trial is to assess the safety and efficacy of Adrenomedullin in CADASIL patients.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)